Sona Nanotech reported results from a first‑in‑human feasibility study treating 10 patients with immunotherapy‑resistant metastatic melanoma using its Targeted Hyperthermia Therapy (THT). By day 15, 8 of 10 patients showed a clinical response; six of those eight had no detectable residual melanoma on representative biopsies. Two patients showed no response. Sona said the outcomes exceeded expectations and validated earlier preclinical work; the company is preparing a Canadian clinical trial and has applied for an Investigational Testing Authorization with Health Canada. Investigators and Sona executives characterized the rapid, measurable tumor regressions as encouraging for further development in solid tumors resistant to standard immunotherapy.